These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2157999)

  • 1. Chronic blockade of D2 but not D1 dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by kelatorphan, administered in the accumbens in rats.
    Maldonado R; Daugé V; Feger J; Roques BP
    Neuropharmacology; 1990 Mar; 29(3):215-23. PubMed ID: 2157999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of dopamine receptors reverses the behavioral effects of endogenous enkephalins in the Nucleus caudatus but not in the Nucleus accumbens: differential involvement of delta and mu opioid receptors.
    Daugé V; Rossignol P; Roques BP
    Psychopharmacology (Berl); 1989; 99(2):168-75. PubMed ID: 2572028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localization of dopamine receptor subtypes occupied by intra-accumbens antagonists that reverse cocaine-induced locomotion.
    Neisewander JL; O'Dell LE; Redmond JC
    Brain Res; 1995 Feb; 671(2):201-12. PubMed ID: 7743209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kelatorphan, a potent enkephalinases inhibitor, and opioid receptor agonists DAGO and DTLET, differentially modulate self-stimulation behaviour depending on the site of administration.
    de Witte P; Heidbreder C; Roques BP
    Neuropharmacology; 1989 Jul; 28(7):667-76. PubMed ID: 2761678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the behavioural effects induced by administration in rat nucleus accumbens or nucleus caudatus of selective mu and delta opioid peptides or kelatorphan an inhibitor of enkephalin-degrading-enzymes.
    Daugé V; Rossignol P; Roques BP
    Psychopharmacology (Berl); 1988; 96(3):343-52. PubMed ID: 2851851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects induced by chronic treatment with selective D1 or D2 antagonists on open-field behavior and colonic temperature.
    Maldonado R; Baamonde A; Daugé V; Féger J
    Fundam Clin Pharmacol; 1990; 4(3):341-56. PubMed ID: 2142927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of dopamine D2 receptors induces an analgesia involving an opioidergic but non enkephalinergic link.
    Michael-Titus A; Bousselmame R; Costentin J
    Eur J Pharmacol; 1990 Oct; 187(2):201-7. PubMed ID: 2176983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy.
    Ossowska K; Karcz M; Wardas J; Wolfarth S
    Eur J Pharmacol; 1990 Jul; 182(2):327-34. PubMed ID: 1975782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lesion of dopamine mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by a mu-opioid receptor agonist.
    Calenco-Choukroun G; Daugé V; Gacel G; Roques BP
    Eur J Pharmacol; 1991 Dec; 209(3):267-71. PubMed ID: 1665799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation.
    Baamonde A; Daugé V; Ruiz-Gayo M; Fulga IG; Turcaud S; Fournié-Zaluski MC; Roques BP
    Eur J Pharmacol; 1992 Jun; 216(2):157-66. PubMed ID: 1327810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of a delta opioid receptor agonist but not a mu opioid receptor agonist with the D1-selective dopamine receptor agonist SKF 38393 markedly potentiates different behaviors in mice.
    Toyoshi T; Ukai M; Kameyama T
    Eur J Pharmacol; 1992 Mar; 213(1):25-30. PubMed ID: 1354161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of enkephalin metabolism and activation of mu- or delta-opioid receptors elicit opposite effects on reward and motility in the ventral mesencephalon.
    Heidbreder C; Gewiss M; Lallemand S; Roques BP; De Witte P
    Neuropharmacology; 1992 Mar; 31(3):293-8. PubMed ID: 1321359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mu-opioid receptors mediate the inhibitory effect of opioids on dopamine-sensitive adenylate cyclase in primary cultures of rat neostriatal neurons.
    Van Vliet BJ; Mulder AH; Schoffelmeer AN
    J Neurochem; 1990 Oct; 55(4):1274-80. PubMed ID: 2168934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation rearing impairs the reinforcing efficacy of intravenous cocaine or intra-accumbens d-amphetamine: impaired response to intra-accumbens D1 and D2/D3 dopamine receptor antagonists.
    Phillips GD; Howes SR; Whitelaw RB; Robbins TW; Everitt BJ
    Psychopharmacology (Berl); 1994 Jul; 115(3):419-29. PubMed ID: 7871084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment.
    Cordonnier L; Sanchez M; Roques BP; Noble F
    Neuroscience; 2005; 135(1):1-10. PubMed ID: 16084652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesoaccumbens dopamine-opiate interactions in the control over behaviour by a conditioned reinforcer.
    Phillips GD; Robbins TW; Everitt BJ
    Psychopharmacology (Berl); 1994 Mar; 114(2):345-59. PubMed ID: 7838928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1 and D2 dopamine receptor mediation of amphetamine-induced acetylcholine release in nucleus accumbens.
    Keys AS; Mark GP
    Neuroscience; 1998 Sep; 86(2):521-31. PubMed ID: 9881866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic system mediates only delta-opiate inhibition of endogenous acetylcholine release evoked by glutamate from rat striatal slices.
    Arenas E; Alberch J; Marsal J
    Neuroscience; 1991; 42(3):707-14. PubMed ID: 1683474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The actions of (-)N-n-propylnorapomorphine and selective dopamine D1 and D2 receptor agonists to modify the release of [3H]dopamine from the rat nucleus accumbens.
    Barnes JM; Barnes NM; Costall B; Naylor RJ
    Neuropharmacology; 1990 Apr; 29(4):327-36. PubMed ID: 1971430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.